|
JP6855661B2
(ja)
*
|
2012-10-23 |
2021-04-07 |
シンアフィックス ビー．ブイ． |
修飾抗体、抗体コンジュゲート及びそれらを調製する方法
|
|
KR102306490B1
(ko)
|
2013-03-15 |
2021-09-28 |
리제너론 파아마슈티컬스, 인크. |
생물학적 활성 분자, 그의 접합체 및 치료 용도
|
|
PL2991683T3
(pl)
*
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
|
SG11201601230RA
(en)
|
2013-08-26 |
2016-03-30 |
Regeneron Pharma |
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
|
|
EP2935608A1
(en)
*
|
2013-10-14 |
2015-10-28 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
WO2015057066A1
(en)
*
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
EP3058083B1
(en)
|
2013-10-14 |
2018-04-11 |
SynAffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
CN105764491A
(zh)
|
2013-12-09 |
2016-07-13 |
度瑞公司 |
药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
|
|
EP3097079B1
(en)
|
2014-01-24 |
2021-05-12 |
SynAffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
US10905678B2
(en)
|
2014-04-08 |
2021-02-02 |
University Of Georgia Research Foundation, Inc. |
Site-specific antibody-drug glycoconjugates and methods
|
|
AU2015282627B2
(en)
|
2014-06-30 |
2020-04-02 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
EP2974744A1
(en)
|
2014-07-16 |
2016-01-20 |
Stichting Katholieke Universiteit |
Strain-promoted oxidation controlled cycloaddition with high reaction rate
|
|
US11046988B2
(en)
|
2014-08-04 |
2021-06-29 |
Synaffix B.V. |
Process for the modification of a glycoprotein using a β-(1,4)-N-acetylgalactosaminyl transferase or a mutant thereof
|
|
ES2740907T3
(es)
*
|
2014-10-03 |
2020-02-07 |
Synaffix Bv |
Enlazador de sulfamida, conjugados de los mismos y métodos de preparación
|
|
CN114656483A
(zh)
*
|
2014-12-04 |
2022-06-24 |
细胞基因公司 |
生物分子共轭物
|
|
JP6595600B2
(ja)
*
|
2014-12-31 |
2019-10-23 |
ディヴェロップメント センター フォー バイオテクノロジー |
糖タンパク質連鎖による部位特異的な複合体形成およびその方法
|
|
US11559581B2
(en)
*
|
2015-01-09 |
2023-01-24 |
Oxford University Innovation Limited |
Antibody conjugates and methods of making the antibody conjugates
|
|
CN107995912A
(zh)
|
2015-03-27 |
2018-05-04 |
里珍纳龙药品有限公司 |
美登素类衍生物、其偶联物和使用方法
|
|
EP3134520B1
(en)
|
2015-04-23 |
2017-12-20 |
Synaffix B.V. |
Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a (1,4)-n-acetylgalactosaminyltransferase
|
|
WO2016172615A1
(en)
*
|
2015-04-24 |
2016-10-27 |
University Of Delaware |
Synthetic n-acetyl-muramic acid derivatives and uses thereof
|
|
KR20180025865A
(ko)
|
2015-07-06 |
2018-03-09 |
리제너론 파마슈티칼스 인코포레이티드 |
다중특이적 항원 결합 분자 및 이의 용도
|
|
CA2995145C
(en)
*
|
2015-08-26 |
2023-08-01 |
Vib Vzw |
Means and methods for monitoring inflammation
|
|
KR20180058737A
(ko)
|
2015-10-07 |
2018-06-01 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체
|
|
TWI660741B
(zh)
|
2015-11-03 |
2019-06-01 |
財團法人工業技術研究院 |
抗體藥物複合物及其製造方法
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
MX390630B
(es)
|
2016-01-25 |
2025-03-21 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
|
|
JP6991978B2
(ja)
*
|
2016-01-27 |
2022-02-03 |
メディミューン，エルエルシー |
定められるグリコシル化パターンを有する抗体を調製するための方法
|
|
WO2017137457A1
(en)
|
2016-02-08 |
2017-08-17 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
JP2017197512A
(ja)
*
|
2016-02-08 |
2017-11-02 |
シンアフィックス ビー．ブイ． |
Ｃｄ３０腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
EP3413916A1
(en)
*
|
2016-02-08 |
2018-12-19 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
EP3413920A1
(en)
|
2016-02-08 |
2018-12-19 |
Synaffix B.V. |
Bioconjugates containing sulfamide linkers for use in treatment
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
JP2017200902A
(ja)
*
|
2016-02-08 |
2017-11-09 |
シンアフィックス ビー．ブイ． |
Ｈｅｒ２腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
|
|
US11590239B2
(en)
*
|
2016-02-08 |
2023-02-28 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
EP3414328B1
(en)
|
2016-02-08 |
2024-01-10 |
Synaffix B.V. |
Enzymes for trimming of glycoproteins
|
|
KR102456433B1
(ko)
|
2016-03-02 |
2022-10-19 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
에리불린-기반 항체-약물 콘주게이트 및 사용 방법
|
|
US11352446B2
(en)
|
2016-04-28 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
WO2017191817A1
(ja)
*
|
2016-05-02 |
2017-11-09 |
味の素株式会社 |
アジド基含有Ｆｃタンパク質
|
|
WO2017218891A1
(en)
*
|
2016-06-17 |
2017-12-21 |
Life Technologies Corporation |
Site-specific crosslinking of antibodies
|
|
CN121021395A
(zh)
|
2016-06-28 |
2025-11-28 |
文塔纳医疗系统公司 |
点击化学用于ihc和ish测定中的信号扩增的应用
|
|
WO2018003983A1
(ja)
*
|
2016-07-01 |
2018-01-04 |
第一三共株式会社 |
ｈＡＮＰ－Ｆｃ含有分子コンジュゲート
|
|
JP2019524687A
(ja)
|
2016-07-01 |
2019-09-05 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
抗体薬物複合体およびこれを用いた治療方法
|
|
AU2017331361B2
(en)
*
|
2016-09-23 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
|
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
|
AU2017359043B2
(en)
|
2016-11-08 |
2022-06-16 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
|
US11628225B2
(en)
*
|
2016-11-14 |
2023-04-18 |
CHO Pharma Inc. |
Antibody-drug conjugates
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
US11085062B2
(en)
|
2016-12-29 |
2021-08-10 |
Development Center For Biotechnology |
Processes for preparing glycoprotein-drug conjugates
|
|
WO2018141959A1
(en)
|
2017-02-06 |
2018-08-09 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
CN110520161A
(zh)
*
|
2017-02-10 |
2019-11-29 |
伊利诺伊大学评议会 |
用于癌症选择性标记和靶向的触发器可激活的糖缀合物
|
|
WO2018206734A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
|
CN111065622A
(zh)
|
2017-05-18 |
2020-04-24 |
里珍纳龙药品有限公司 |
双八氢菲羧酰胺类化合物及其蛋白质偶联物
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
CN110809583A
(zh)
|
2017-06-07 |
2020-02-18 |
瑞泽恩制药公司 |
用于内化酶的组合物和方法
|
|
EP3665161B1
(en)
|
2017-08-09 |
2023-09-27 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
New targeted cytotoxic ratjadone derivatives and conjugates thereof
|
|
EP3441766B1
(en)
*
|
2017-08-11 |
2020-03-11 |
Life Science Inkubator Sachsen GmbH & Co. KG |
Novel antibody conjugates suitable for use in discrete fluorescence quenching displacement immunoassays
|
|
IL301638B2
(en)
*
|
2017-09-29 |
2024-09-01 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
CA3080857A1
(en)
|
2017-11-07 |
2019-05-16 |
Regeneron Pharmaceuticals, Inc. |
Hydrophilic linkers for antibody drug conjugates
|
|
CN111727075B
(zh)
|
2017-11-27 |
2024-04-05 |
普渡制药公司 |
靶向人组织因子的人源化抗体
|
|
WO2019110725A1
(en)
|
2017-12-06 |
2019-06-13 |
Synaffix B.V. |
Enediyne conjugates
|
|
BR112020013198A2
(pt)
|
2017-12-29 |
2020-12-01 |
Glycomimetics, Inc. |
inibidores heterobifuncionais de e-selectina e galectina-3
|
|
EA202091672A1
(ru)
|
2018-01-08 |
2021-02-01 |
Регенерон Фармасьютикалз, Инк. |
Стероиды и их антитело-конъюгаты
|
|
JP7328990B2
(ja)
|
2018-04-30 |
2023-08-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
|
|
WO2019217591A1
(en)
|
2018-05-09 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-msr1 antibodies and methods of use thereof
|
|
MX2020012350A
(es)
|
2018-05-17 |
2021-01-29 |
Regeneron Pharma |
Anticuerpos anti-cd63, conjugados y usos de estos.
|
|
JP2019206491A
(ja)
*
|
2018-05-29 |
2019-12-05 |
国立研究開発法人理化学研究所 |
乳がんまたは胃がんの治療のための抗体−薬物複合体
|
|
EP3806905B1
(en)
*
|
2018-06-15 |
2024-08-07 |
Shanghai Miracogen Inc. |
Methods and materials for treating cancer
|
|
JP2021533200A
(ja)
|
2018-08-02 |
2021-12-02 |
ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. |
顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US20210308273A1
(en)
|
2018-08-02 |
2021-10-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11911484B2
(en)
*
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN112930197A
(zh)
*
|
2018-08-02 |
2021-06-08 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
MX2021001283A
(es)
*
|
2018-08-02 |
2021-07-15 |
Dyne Therapeutics Inc |
Complejos dirigidos al músculo y sus usos para tratar la distrofia miotónica.
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP3876998A1
(en)
|
2018-11-05 |
2021-09-15 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
MY206542A
(en)
|
2018-11-20 |
2024-12-20 |
Regeneron Pharma |
Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
|
|
EP3898651A2
(en)
|
2018-12-21 |
2021-10-27 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
CN113226470B
(zh)
|
2018-12-21 |
2025-05-06 |
瑞泽恩制药公司 |
利福霉素类似物及其抗体-药物缀合物
|
|
KR20210110645A
(ko)
|
2018-12-27 |
2021-09-08 |
글리코미메틱스, 인크. |
갈렉틴-3 억제 c-글리코사이드
|
|
WO2020139962A1
(en)
|
2018-12-27 |
2020-07-02 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
|
KR102877468B1
(ko)
|
2019-01-08 |
2025-10-29 |
리제너론 파마슈티칼스 인코포레이티드 |
흔적이 없는 링커 및 이의 단백질-접합체
|
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
|
WO2020172475A1
(en)
|
2019-02-21 |
2020-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
|
JP7627655B2
(ja)
*
|
2019-03-25 |
2025-02-06 |
第一三共株式会社 |
抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
WO2020196475A1
(ja)
*
|
2019-03-25 |
2020-10-01 |
第一三共株式会社 |
抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
CA3139180A1
(en)
*
|
2019-03-27 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
|
WO2020245229A1
(en)
|
2019-06-03 |
2020-12-10 |
Synaffix B.V. |
Acetal-based cleavable linkers
|
|
KR20220063185A
(ko)
|
2019-09-16 |
2022-05-17 |
리제너론 파마슈티칼스 인코포레이티드 |
면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
|
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
|
KR102834656B1
(ko)
*
|
2019-09-29 |
2025-07-17 |
맙플렉스 인터내셔널 컴퍼니 리미티드 |
산 방법에 의한 항체-약물 접합체 중간체의 제조 방법 및 이의 적용
|
|
GB201917388D0
(en)
*
|
2019-11-28 |
2020-01-15 |
Cambridge Entpr Ltd |
Novel linker compounds
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
TW202140075A
(zh)
|
2020-01-09 |
2021-11-01 |
美商梅爾莎納醫療公司 |
具有含肽之連接子的位置特異性抗體－藥物共軛體
|
|
CN115768483A
(zh)
|
2020-01-13 |
2023-03-07 |
西纳福克斯股份有限公司 |
抗体与免疫细胞衔接器的缀合物
|
|
EP4090379A1
(en)
|
2020-01-13 |
2022-11-23 |
Synaffix B.V. |
Via cycloaddition bilaterally functionalized antibodies
|
|
EP4090376A1
(en)
|
2020-01-13 |
2022-11-23 |
Synaffix B.V. |
Via cycloaddition bilaterally functionalized antibodies
|
|
JP2023511956A
(ja)
|
2020-01-24 |
2023-03-23 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
タンパク質－抗ウイルス化合物コンジュゲート
|
|
WO2021174113A1
(en)
|
2020-02-28 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind her2, and methods of use thereof
|
|
IL319200A
(en)
|
2020-04-16 |
2025-04-01 |
Regeneron Pharma |
Antibody-drug conjugates prepared using Diels-Alder compression methods
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
US20230183347A1
(en)
|
2020-05-25 |
2023-06-15 |
Foundation For Biomedical Research And Innovation At Kobe |
PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease
|
|
CN111560078A
(zh)
*
|
2020-06-19 |
2020-08-21 |
联宁（苏州）生物制药有限公司 |
具有马来酰亚胺接头的双臂中间体及其合成方法
|
|
JP2023533218A
(ja)
|
2020-06-24 |
2023-08-02 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
ツブリシン及びタンパク質－ツブリシンコンジュゲート
|
|
EP4172141A1
(en)
|
2020-06-26 |
2023-05-03 |
Synaffix B.V. |
Methods for the preparation of linker payload constructs
|
|
US20220072141A1
(en)
|
2020-07-13 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
|
|
NL2026400B1
(en)
|
2020-09-02 |
2022-05-04 |
Synaffix Bv |
Methods for the preparation of bioconjugates
|
|
WO2022056494A1
(en)
|
2020-09-14 |
2022-03-17 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
WO2022058395A1
(en)
|
2020-09-15 |
2022-03-24 |
Synaffix B.V. |
Antibody-exatecan conjugates
|
|
WO2022081895A1
(en)
|
2020-10-16 |
2022-04-21 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
KR20230095070A
(ko)
|
2020-10-22 |
2023-06-28 |
리제너론 파마슈티칼스 인코포레이티드 |
항-fgfr2 항체 및 이의 사용 방법
|
|
NL2026947B1
(en)
|
2020-11-20 |
2022-07-01 |
Synaffix Bv |
Tyrosine-based antibody conjugates
|
|
EP4267195A1
(en)
|
2020-12-24 |
2023-11-01 |
Synaffix B.V. |
Glycan-conjugated antibodies binding to fc-gamma receptor
|
|
EP4271816A4
(en)
|
2020-12-31 |
2025-04-02 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
|
|
US20250262314A1
(en)
|
2021-02-08 |
2025-08-21 |
Synaffix B.V. |
Multifunctional antibodies
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
|
US11648318B2
(en)
|
2021-07-09 |
2023-05-16 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TFR) antibody and uses thereof
|
|
EP4366784A1
(en)
|
2021-07-09 |
2024-05-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
IL307947A
(en)
|
2021-07-28 |
2023-12-01 |
Regeneron Pharma |
An antiviral compound of proteins
|
|
US20240350658A1
(en)
*
|
2021-10-20 |
2024-10-24 |
Glyco-Therapy Biotechnology Co., Ltd. |
Site-specific glycoprotein conjugates and methods for making the same
|
|
KR102782629B1
(ko)
*
|
2021-11-12 |
2025-03-19 |
닥터아이앤비(주) |
생산 시간을 단축하고 안정성이 개선된 의약품 제조방법
|
|
CA3235096A1
(en)
|
2021-11-17 |
2023-05-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
|
US20230414775A1
(en)
|
2021-12-29 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
JP2025502147A
(ja)
|
2022-01-12 |
2025-01-24 |
リジェネロン ファーマシューティカルズ，インク． |
タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用
|
|
WO2023137443A1
(en)
|
2022-01-14 |
2023-07-20 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
|
WO2023141855A1
(en)
*
|
2022-01-27 |
2023-08-03 |
Glyco-Therapy Biotechnology Co., Ltd. |
Protein conjugates with multiple payloads and methods for making the same
|
|
MX2024010267A
(es)
|
2022-02-22 |
2024-08-28 |
Adc Therapeutics Sa |
Método de conjugación que incluye una transglutaminasa en la región fc que comprende un n-glicano recortado.
|
|
JP2025512735A
(ja)
|
2022-03-11 |
2025-04-22 |
リジェネロン ファーマシューティカルズ，インク． |
Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用
|
|
JP2025510678A
(ja)
|
2022-03-23 |
2025-04-15 |
シンアフィックス ビー．ブイ． |
カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート
|
|
AU2023241225A1
(en)
|
2022-03-23 |
2024-08-29 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
WO2023180490A1
(en)
|
2022-03-23 |
2023-09-28 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing nectin-4
|
|
CN120826241A
(zh)
|
2022-03-23 |
2025-10-21 |
新锐生物技术公司 |
用于靶向表达ptk7的肿瘤的抗体缀合物
|
|
KR20250004770A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
|
|
EP4285934A1
(en)
|
2022-05-30 |
2023-12-06 |
CER Groupe |
Modified trimannose-oligosacharides, bisected n-glycans comprising said trimannose core and method for obtaining them
|
|
WO2024020164A2
(en)
|
2022-07-21 |
2024-01-25 |
Firefly Bio, Inc. |
Glucocorticoid receptor agonists and conjugates thereof
|
|
EP4572798A1
(en)
|
2022-08-15 |
2025-06-25 |
Synaffix B.V. |
Anthracyclins and conjugates thereof
|
|
EP4344707A1
(en)
|
2022-09-29 |
2024-04-03 |
Emergence Therapeutics AG |
New anti-nectin-4 antibody drug conjugates
|
|
KR20250128394A
(ko)
|
2022-11-30 |
2025-08-27 |
리제너론 파마슈티칼스 인코포레이티드 |
Tlr7 작용제 및 이의 항체-약물-접합체
|
|
WO2024121123A1
(en)
|
2022-12-06 |
2024-06-13 |
Synaffix B.V. |
Synthesis of endo-bicyclononene
|
|
CN120752059A
(zh)
|
2022-12-21 |
2025-10-03 |
瑞泽恩制药公司 |
用于adc缀合的拓扑异构酶i抑制剂的前药及其使用方法
|
|
AU2023409727A1
(en)
*
|
2022-12-22 |
2025-08-07 |
Janssen Pharmaceutica Nv |
Methods of preparing antibody-polynucleotide conjugates
|
|
EP4389152A1
(en)
|
2022-12-23 |
2024-06-26 |
Synaffix B.V. |
Conjugates of pbd prodrugs
|
|
WO2024150074A2
(en)
|
2023-01-13 |
2024-07-18 |
Takeda Pharmaceutical Company Limited |
Coronavirus antibodies and therapeutic uses thereof
|
|
EP4653020A1
(en)
|
2023-01-19 |
2025-11-26 |
Shanghai Shengdi Pharmaceutical Co., Ltd |
Tyrosinase-mediated protein site-specific conjugation and use thereof
|
|
EP4410313A1
(en)
|
2023-01-31 |
2024-08-07 |
Synaffix B.V. |
Homogeneous antibody-conjugates with high payload loading
|
|
WO2024168199A1
(en)
|
2023-02-09 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates via inverse electron demand diels-alder reactions
|
|
KR20250158054A
(ko)
|
2023-03-02 |
2025-11-05 |
알로이 테라퓨틱스, 인크. |
항-cd22 항체 및 이의 용도
|
|
WO2024199442A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Disaccharide linker, linker-payload containing the same and glycan chain-remodeled antibody-drug conjugate, preparation method and uses thereof
|
|
WO2024199432A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Site-speicfic orthogonal bioconjugate modality and application thereof
|
|
EP4450093A1
(en)
|
2023-04-17 |
2024-10-23 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
WO2024218164A1
(en)
|
2023-04-17 |
2024-10-24 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
EP4450489A1
(en)
|
2023-04-18 |
2024-10-23 |
Synaffix B.V. |
Stable 4-isoxazoline conjugates
|
|
WO2024229105A1
(en)
|
2023-05-02 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
CN121079319A
(zh)
|
2023-05-08 |
2025-12-05 |
赛诺菲 |
免疫球蛋白单可变结构域的糖基化
|
|
WO2024251826A1
(en)
|
2023-06-05 |
2024-12-12 |
Vib Vzw |
Glyco-engineered antibody-drug-conjugates comprising an oxime linker
|
|
WO2025011557A1
(en)
*
|
2023-07-10 |
2025-01-16 |
Surio Therapeutics Co. Ltd |
Functionalized auristatins, pharmaceutical compositions, and therapeutic applications
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
WO2025024334A1
(en)
|
2023-07-21 |
2025-01-30 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
EP4541376A1
(en)
|
2023-10-17 |
2025-04-23 |
ADC Therapeutics SA |
Antibody-drug conjugates
|
|
WO2025096921A1
(en)
|
2023-11-03 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
EP4574174A1
(en)
|
2023-12-19 |
2025-06-25 |
Jack Elands |
Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025163120A1
(en)
|
2024-02-01 |
2025-08-07 |
Adcytherix Sas |
ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
|
|
WO2025172468A1
(en)
|
2024-02-13 |
2025-08-21 |
Synaffix B.V. |
Method for producing azido-sugars and compounds obtained thereby
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025238253A1
(en)
|
2024-05-16 |
2025-11-20 |
Synaffix B.V. |
Antibody-oligonucleotide conjugates
|